ProfileGDS5678 / 1451259_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 91% 91% 90% 91% 90% 88% 90% 90% 89% 90% 89% 90% 91% 90% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.3187691
GSM967853U87-EV human glioblastoma xenograft - Control 27.3936391
GSM967854U87-EV human glioblastoma xenograft - Control 37.2761490
GSM967855U87-EV human glioblastoma xenograft - Control 47.6309791
GSM967856U87-EV human glioblastoma xenograft - Control 57.2239890
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.6886888
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.0706490
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.1941690
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.0168689
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.2916790
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.9948789
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.2464990
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.4581891
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.2101290